Novel treatments of fibrosis for hypertensive heart disease

Widdop, Robert (Primary Chief Investigator (PCI))
Aguilar, Mibel (Chief Investigator (CI))
Denton, Katherine (Chief Investigator (CI))

Project: Research

Status	Finished
Effective start/end date	1/01/17 → 31/12/20

Funding

National Health and Medical Research Council (NHMRC) (Australia): AUD912,536.00

1 Article
1 Review Article

Serelaxin and the AT₂ Receptor Agonist CGP42112 Evoked a Similar, Nonadditive, Cardiac Antifibrotic Effect in High Salt-Fed Mice That Were Refractory to Candesartan Cilexetil
Wang, Y., Han, L., Shen, M., Jones, E. S., Spizzo, I., Walton, S. L., Denton, K. M., Gaspari, T. A., Samuel, C. S. & Widdop, R. E., 14 Feb 2020, In: ACS Pharmacology & Translational Science. 3, 1, p. 76-87 12 p.
Research output: Contribution to journal › Article › Research › peer-review

Open Access
File

3 Citations (Scopus)
Anti-fibrotic potential of AT₂ receptor agonists
Wang, Y., Del Borgo, M., Lee, H. W., Baraldi, D., Hirmiz, B., Gaspari, T. A., Denton, K. M., Aguilar, M-I., Samuel, C. S. & Widdop, R. E., 31 Aug 2017, In: Frontiers in Pharmacology. 8, 7 p., 564.
Research output: Contribution to journal › Review Article › Research › peer-review

Open Access
File

41 Citations (Scopus)

Animal Research Platform (MARP)
Tanya Lennane (Manager)
Faculty of Medicine Nursing and Health Sciences Research Platforms
Facility/equipment: Facility
Biomedical Imaging (MBI)
Gary Egan (Manager) & Kylie Reid (Manager)
Office of the Vice-Provost (Research and Research Infrastructure)
Facility/equipment: Facility
Histology Platform
Camilla Cohen (Manager)
Faculty of Medicine Nursing and Health Sciences Research Platforms
Facility/equipment: Facility